Page last updated: 2024-09-03

gefitinib and Chemical and Drug Induced Liver Injury

gefitinib has been researched along with Chemical and Drug Induced Liver Injury in 33 studies

Research

Studies (33)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (18.18)	29.6817
2010's	22 (66.67)	24.3611
2020's	5 (15.15)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C	1
Imamura, CK; Kawamura, T; Kenmotsu, H; Murakami, H; Mushiroda, T; Naito, T; Nakashima, K; Omori, S; Ono, A; Taira, T; Takahashi, T; Tanigawara, Y; Wakuda, K	1
Miyazaki, N; Oda, S; Tsuneyama, K; Yokoi, T	1
Chen, X; Du, J; He, Q; Jin, Y; Lin, N; Luo, P; Shao, J; Xu, Z; Yan, H; Yang, B; Zhang, Y	1
Cai, Y; He, MF; Jiang, LL; Li, CY; Wei, P; Zhang, SR; Zhang, Y	1
Cho, S; Gwak, HS; Jeong Rhie, S; Kim, JY; Yee, J	1
Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N	1
Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K	1
Nakagawa, K; Okamoto, I; Takeda, M	1
Dong, M; He, X; Li, J; Wang, J; Wang, Y; Wang, Z; Wu, Y	1
Atobe, O; Fujimori, A; Hachiya, T; Ikuyama, Y; Imai, A; Shiba, H; Sonehara, K	1
Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H	1
Goto, K; Kirita, K; Matsumoto, S; Niho, S; Ohmatsu, H; Sugiyama, E; Umemura, S; Yoh, K; Zenke, Y	1
Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Minami, D; Ninomiya, K; Ninomiya, T; Oda, N; Ohashi, K; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M; Yoshioka, H	1
Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M	1
Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N	1
Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y	1
Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Takaiwa, T; Yoshioka, H	1
Chen, J; Dassarath, M; Gu, R; Wang, Q; Wu, G; Yang, K; Yin, Z	1
Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S	1
Fujimura, M; Kasahara, K; Kimura, H; Kita, T; Nakao, S; Yoshimoto, A	1
Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T	1
Anderson, F; Bebb, G; Davis, J; Ho, C; Murray, N	1
Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S	1
Eguchi, K; Seki, N; Shibakuki, R; Uematsu, K	1
Carlini, P; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Milella, M; Nuzzo, C; Papaldo, P; Ruggeri, EM	1

Reviews

2 review(s) available for gefitinib and Chemical and Drug Induced Liver Injury

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:1 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines	2015

Other Studies

31 other study(ies) available for gefitinib and Chemical and Drug Induced Liver Injury

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology, 2011, Volume: 7, Issue:12 Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index	2014
Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells. The Journal of pharmacy and pharmacology, 2023, Mar-12, Volume: 75, Issue:3 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Quinazolines; RNA, Messenger	2023
Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged	2020
Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice. The Journal of toxicological sciences, 2020, Volume: 45, Issue:8 Topics: Animals; Buthionine Sulfoximine; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Disease Progression; Gefitinib; Glutathione; Liver; Mice, Inbred C57BL; Oxidative Stress; Protein Kinase Inhibitors	2020
PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy, 2021, Volume: 17, Issue:10 Topics: Animals; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Chemical and Drug Induced Liver Injury; Electron Transport Complex IV; Gefitinib; Lung Neoplasms; Mice; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins	2021
Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib. Toxicology letters, 2021, Jun-01, Volume: 343 Topics: Afatinib; Animals; Animals, Genetically Modified; Chemical and Drug Induced Liver Injury; Embryo, Nonmammalian; Gefitinib; Gene Expression Regulation; Liver; Protein Kinase Inhibitors; Zebrafish	2021
Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity. Journal of clinical pharmacology, 2018, Volume: 58, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Interactions; ErbB Receptors; Female; Gefitinib; Histamine H2 Antagonists; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors	2018
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2013, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines	2013
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity. Anticancer research, 2014, Volume: 34, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2014
Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. Anti-cancer drugs, 2016, Volume: 27, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Time Factors	2016
[Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:1 Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2016
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. Investigational new drugs, 2016, Volume: 34, Issue:6 Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents	2016
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2016, Volume: 99 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; ErbB Receptors; Gefitinib; Glucuronosyltransferase; Humans; Lung Neoplasms; Middle Aged; Mutation; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Retreatment; Treatment Outcome	2016
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Gefitinib; Humans; Liver Function Tests; Lung Neoplasms; Male; Middle Aged; Mutation; Overweight; Quinazolines; Retrospective Studies; Risk Factors	2016
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-10, Volume: 28, Issue:17 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines	2010
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines	2010
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome	2011
Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2012
Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer. Onkologie, 2012, Volume: 35, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Liver Neoplasms; Middle Aged; Quinazolines; Treatment Outcome	2012
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2013
[Transient liver injury caused by gefitinib]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2004, Volume: 42, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Quinazolines	2004
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies	2005
Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-20, Volume: 23, Issue:33 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines	2005
Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 52, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies	2006
Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Middle Aged; Quinazolines	2006
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-10, Volume: 24, Issue:35 Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gefitinib; Humans; Isoenzymes; Lymphatic Metastasis; Middle Aged; Nitriles; Quinazolines; Triazoles	2006